The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

作者: Andrew Spencer , Sung-Soo Yoon , Simon J. Harrison , Shannon R. Morris , Deborah A. Smith

DOI: 10.1182/BLOOD-2014-03-559963

关键词:

摘要: … Perifosine, a putative AKT inhibitor, recently failed to … of pure AKT inhibition in MM. We believe our study is important because afuresertib remains the only highly specific AKT inhibitor …

参考文章(26)
Andrew Spencer, Keith Stewart, Joanna B Opalinska, Joanna B Opalinska, Shang-Yi Huang, Shang-Yi Huang, Michael E O'Dwyer, Michael E O'Dwyer, Ajai Chari, Ajai Chari, Suzanne Trudel, Michael Rosenzwieg, Michael Rosenzwieg, Jennifer Gauvin, Jennifer Gauvin, Peter M Voorhees, Peter M Voorhees, Craig C Hofmeister, Craig C Hofmeister, Joyce M Antal, Joyce M Antal, Heather J. Sutherland, Heather J. Sutherland, Deborah A Smith, Deborah A Smith, Cara A Rosenbaum, Cara A Rosenbaum, Ajay K. Nooka, Ajay K. Nooka, Ademi Santiago-Walker, Ademi Santiago-Walker, Chb Chb, Chb Chb, Andrew Spencer, Novel AKT Inhibitor Afuresertib In Combination With Bortezomib and Dexamethasone Demonstrates Favorable Safety Profile and Significant Clinical Activity In Patients With Relapsed/Refractory Multiple Myeloma Blood. ,vol. 122, pp. 283- 283 ,(2013) , 10.1182/BLOOD.V122.21.283.283
Craig Cherrin, Kathleen Haskell, Bonnie Howell, Raymond Jones, Karen Leander, Ronald Robinson, Aubrey Watkins, Mark Bilodeau, Jacob Hoffman, Philip Sanderson, George Hartman, Elizabeth Mahan, Thomayant Prueksaritanont, Guoqiang Jiang, Qing-Bai She, Neal Rosen, Laura Sepp-Lorenzino, Deborah Defeo-Jones, Hans E. Huber, An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo Cancer Biology & Therapy. ,vol. 9, pp. 493- 503 ,(2010) , 10.4161/CBT.9.7.11100
Jeffrey A. Engelman, Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nature Reviews Cancer. ,vol. 9, pp. 550- 562 ,(2009) , 10.1038/NRC2664
Shaji K. Kumar, Terry M. Therneau, Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri, S. Vincent Rajkumar, Rafael Fonseca, Thomas E. Witzig, John A. Lust, Dirk R. Larson, Robert A. Kyle, Philip R. Greipp, Clinical Course of Patients With Relapsed Multiple Myeloma Mayo Clinic Proceedings. ,vol. 79, pp. 867- 874 ,(2004) , 10.4065/79.7.867
V Munugalavadla, S Mariathasan, D Slaga, C Du, L Berry, G Del Rosario, Y Yan, M Boe, L Sun, L S Friedman, M Chesi, P Leif Bergsagel, A Ebens, The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma Oncogene. ,vol. 33, pp. 316- 325 ,(2014) , 10.1038/ONC.2012.594
Torsten Steinbrunn, Thorsten Stühmer, Cyrus Sayehli, Manik Chatterjee, Hermann Einsele, Ralf C. Bargou, Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma British Journal of Haematology. ,vol. 159, pp. 430- 440 ,(2012) , 10.1111/BJH.12039
Douglas W. McMillin, Melissa Ooi, Jake Delmore, Joseph Negri, Patrick Hayden, Nicolas Mitsiades, Jana Jakubikova, Sauveur-Michel Maira, Carlos Garcia-Echeverria, Robert Schlossman, Nikhil C. Munshi, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades, Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 Cancer Research. ,vol. 69, pp. 5835- 5842 ,(2009) , 10.1158/0008-5472.CAN-08-4285
Timothy A. Yap, Li Yan, Amita Patnaik, Ivy Fearen, David Olmos, Kyriakos Papadopoulos, Richard D. Baird, Liliana Delgado, Adekemi Taylor, Lisa Lupinacci, Ruth Riisnaes, Lorna L. Pope, Simon P. Heaton, George Thomas, Michelle D. Garrett, Daniel M. Sullivan, Johann S. de Bono, Anthony W. Tolcher, First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors Journal of Clinical Oncology. ,vol. 29, pp. 4688- 4695 ,(2011) , 10.1200/JCO.2011.35.5263
J S Miguel, J Bladé, B Barlogie, K Anderson, M Gertz, M Dimopoulos, J Westin, P Sonneveld, H Ludwig, G Gahrton, M Beksac, J Crowley, A Belch, M Boccadaro, I Turesson, D Joshua, D Vesole, R Kyle, R Alexanian, G Tricot, M Attal, G Merlini, R Powles, P Richardson, K Shimizu, P Tosi, G Morgan, S V Rajkumar, B G M Durie, , J-L Harousseau, International uniform response criteria for multiple myeloma Leukemia. ,vol. 20, pp. 1467- 1473 ,(2006) , 10.1038/SJ.LEU.2404284
Torsten Steinbrunn, Thorsten Stühmer, Stefan Gattenlöhner, Andreas Rosenwald, Anja Mottok, Christian Unzicker, Hermann Einsele, Manik Chatterjee, Ralf C. Bargou, Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. Blood. ,vol. 117, pp. 1998- 2004 ,(2011) , 10.1182/BLOOD-2010-05-284422